<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04495322</url>
  </required_header>
  <id_info>
    <org_study_id>TG-1000-C-01</org_study_id>
    <nct_id>NCT04495322</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.</brief_title>
  <official_title>A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and to Evaluate the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>R&amp;G Pharma Studies Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics&#xD;
      profiles of TG-1000 in healthy volunteers, and to evaluate the food effect on&#xD;
      pharmacokinetics of single oral dose of TG-1000 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, single-center, randomized, double-blind, placebo-controlled, single-dose&#xD;
      escalation study to evaluate the safety, tolerability, and pharmacokinetics profiles of&#xD;
      TG-1000 in healthy volunteers, and to evaluate the food effect on pharmacokinetics of single&#xD;
      oral dose of TG-1000 in healthy volunteers. The study will be divided into two parts.&#xD;
&#xD;
      Part A is designed as randomized, double-blind, placebo-controlled, sequential, single&#xD;
      ascending oral dose to evaluate the safety, tolerability, and PK profiles of TG-1000 in&#xD;
      healthy volunteers.&#xD;
&#xD;
      Part B is designed as randomized, open-label, two treatment (fasted vs. fed), two-period,&#xD;
      two-sequence crossover to compare the effects of food on the Pharmacokinetic (PK) of single&#xD;
      oral dose of TG-1000 in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single-center, randomized, double-blind, placebo-controlled, single-dose</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects of treatment-emergent adverse events</measure>
    <time_frame>8 days</time_frame>
    <description>Any significant findings after dosing will be considered as adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects of Significant Abnormal Vital Signs Findings</measure>
    <time_frame>8 days</time_frame>
    <description>The systolic and diastolic blood pressure (mmHg), pulse/heart rate (beats/min), respiratory rate (breaths/min), and body temperature (oC) will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects With Significant Abnormal Physical Examination Findings</measure>
    <time_frame>8 days.</time_frame>
    <description>A full general physical examination of the major body systems (General Appearance; Dermatological including skin and nails; Head and Neck; Chest region including Heart and Lung; Abdominal region including Gastrointestinal and Gastroenterology; Back region; Extremities; Psychiatric or Neurological; Lymph nodes; Other) will be performed by investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects With Significant Abnormal 12-lead Electrocardiography (ECG) Findings</measure>
    <time_frame>8 days</time_frame>
    <description>12-lead ECG will be performed after a rest in a supine position. The following ECG parameters will be listed: heart rate, the time between QRS complexes (RR Interval) (ms), the beginning of the P wave to the first deflection of the QRS complex (PR Interval) (ms), first deflection of QRS complex to end of QRS complex at isoelectric line (QRS duration) (ms), first deflection of QRS complex to end of T wave at isoelectric line (QT interval) (ms), Corrected QT interval by Bazett (QTcB) (ms), and Corrected QT interval by - Fridericia (QTcF) (ms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects With Significant Abnormal Holter Electrocardiography (ECG) Findings</measure>
    <time_frame>12 hr pre-dose until 24 hr post-dose</time_frame>
    <description>Holter ECG will be monitor continue from 12 hr pre-dose until 24 hr post-dose. The Investigator will determine whether the results of the Holter monitoring are normal or abnormal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Significant Abnormal Laboratory Values</measure>
    <time_frame>8 days</time_frame>
    <description>Chemistry, Hematology, Coagulation, Urinalysis, Human Immunodeficiency Virus (HIV) test, Hepatitis A virus(HAV) test, Hepatitis B virus (HBV) test, Hepatitis C virus (HCV) test, syphilis, serum pregnancy tests and Breath Alcohol Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile and food effect of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time to Cmax (Tmax)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve from time zero to the time (AUC0-t)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile and food effect of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the concentration-time curve from time zero to infinity (AUC0-inf)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile and food Effect of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>terminal elimination half-life (T1/2, z)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent total body clearance (CL/F)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent total volume distribution (V/F)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration 24 h after dosing (C24)</measure>
    <time_frame>15 days</time_frame>
    <description>Blood sample will be collected to evaluate PK profile of TG-1000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary excretion ratio relative to dose from time zero to the time (Feu0-t)</measure>
    <time_frame>15 days</time_frame>
    <description>Urine sample will be collected to evaluate PK profile of TG-1000.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy Chinese Volunteers</condition>
  <arm_group>
    <arm_group_label>10 mg TG-1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>160 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fasted condition. After washout period, subject will receive a single oral dose of TG-1000 under fed condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fed condition. After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-1000</intervention_name>
    <description>Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.</description>
    <arm_group_label>10 mg TG-1000</arm_group_label>
    <arm_group_label>120 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>160 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>20 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>40 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>80 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)</arm_group_label>
    <arm_group_label>X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.</description>
    <arm_group_label>120 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>160 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>20 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>40 mg TG-1000 or Placebo</arm_group_label>
    <arm_group_label>80 mg TG-1000 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to provide written informed consent.&#xD;
&#xD;
          2. Age 18 (or legal adult age) to 45 years.&#xD;
&#xD;
          3. Body mass index (BMI) in the range of ≥19.0 to ≤ 24.0 kg/m2 and body weight ≥ 50 kg&#xD;
             for male and ≥ 45 kg for female at Screening.&#xD;
&#xD;
          4. Subjects have good communication with Investigator and agree to follow the study&#xD;
             requirement to complete study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormality in 12-lead ECG, chest X-ray, abdominal ultrasounds,&#xD;
             physical examination, vital signs or laboratory values at Screening or Day-1.&#xD;
&#xD;
          2. Positive breath alcohol or urine drug tests at Day-1.&#xD;
&#xD;
          3. Positive test results for Immunoglobulin M anti-HAV antibody, HBsAg, anti-HCV&#xD;
             antibody, HIV or syphilis at Screening.&#xD;
&#xD;
          4. Female subjects with positive pregnancy test results at Screening or Day-1.&#xD;
&#xD;
          5. Male subjects are unwilling to use effective contraception and refrain from sperm&#xD;
             donation from Screening until 3 months after the study drug administration.&#xD;
&#xD;
          6. Current or prior history of any of the following:&#xD;
&#xD;
               1. Significant cardiac disease, diabetes, liver, kidney disease, psychiatric&#xD;
                  diseases or drug abuse or diseases that will affect immunity.&#xD;
&#xD;
               2. Difficulty in swallow or gastrointestinal disorder that could interfere with the&#xD;
                  absorption of the study drug&#xD;
&#xD;
               3. Difficulty in blood sampling or venipuncture&#xD;
&#xD;
               4. Drug allergy or hypersensitivity&#xD;
&#xD;
               5. Blood donation ≥ 400 mL within 3 months before and after study.&#xD;
&#xD;
               6. Alcoholics or frequent drinkers prior to Screening.&#xD;
&#xD;
               7. Frequent smokers prior to Screening.&#xD;
&#xD;
          7. Use of any prohibited medications or surgeries prior to study drug administration:&#xD;
&#xD;
             a. Received any other investigational agents or devices, liver enzyme inducer or&#xD;
             inhibitors, medications including prescriptions, non-prescriptions or herbal remedies,&#xD;
             dietary supplements or surgeries.&#xD;
&#xD;
          8. Unwilling to abstain from alcohol, tobacco, nicotine containing products, caffeine- or&#xD;
             xanthine-containing beverages from Screening until discharge from the phase I unit.&#xD;
&#xD;
          9. Subjects may not be qualified for the study judged by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pingsheng Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04495322
org study id: TG-1000-C-01
nct id: NCT04495322
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics
      profiles of TG-1000 in healthy volunteers, and to evaluate the food effect on
      pharmacokinetics of single oral dose of TG-1000 in healthy volunteers.
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, single-dose
      escalation study to evaluate the safety, tolerability, and pharmacokinetics profiles of
      TG-1000 in healthy volunteers, and to evaluate the food effect on pharmacokinetics of single
      oral dose of TG-1000 in healthy volunteers. The study will be divided into two parts.

      Part A is designed as randomized, double-blind, placebo-controlled, sequential, single
      ascending oral dose to evaluate the safety, tolerability, and PK profiles of TG-1000 in
      healthy volunteers.

      Part B is designed as randomized, open-label, two treatment (fasted vs. fed), two-period,
      two-sequence crossover to compare the effects of food on the Pharmacokinetic (PK) of single
      oral dose of TG-1000 in healthy subjects.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: single-center, randomized, double-blind, placebo-controlled, single-dose
primary purpose: Basic Science
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Number of subjects of treatment-emergent adverse events
time frame: 8 days
description: Any significant findings after dosing will be considered as adverse events.
measure: Number of subjects of Significant Abnormal Vital Signs Findings
time frame: 8 days
description: The systolic and diastolic blood pressure (mmHg), pulse/heart rate (beats/min), respiratory rate (breaths/min), and body temperature (oC) will be measured.
measure: Number of subjects With Significant Abnormal Physical Examination Findings
time frame: 8 days.
description: A full general physical examination of the major body systems (General Appearance; Dermatological including skin and nails; Head and Neck; Chest region including Heart and Lung; Abdominal region including Gastrointestinal and Gastroenterology; Back region; Extremities; Psychiatric or Neurological; Lymph nodes; Other) will be performed by investigator.
measure: Number of subjects With Significant Abnormal 12-lead Electrocardiography (ECG) Findings
time frame: 8 days
description: 12-lead ECG will be performed after a rest in a supine position. The following ECG parameters will be listed: heart rate, the time between QRS complexes (RR Interval) (ms), the beginning of the P wave to the first deflection of the QRS complex (PR Interval) (ms), first deflection of QRS complex to end of QRS complex at isoelectric line (QRS duration) (ms), first deflection of QRS complex to end of T wave at isoelectric line (QT interval) (ms), Corrected QT interval by Bazett (QTcB) (ms), and Corrected QT interval by - Fridericia (QTcF) (ms).
measure: Number of subjects With Significant Abnormal Holter Electrocardiography (ECG) Findings
time frame: 12 hr pre-dose until 24 hr post-dose
description: Holter ECG will be monitor continue from 12 hr pre-dose until 24 hr post-dose. The Investigator will determine whether the results of the Holter monitoring are normal or abnormal.
measure: Number of Participants With Significant Abnormal Laboratory Values
time frame: 8 days
description: Chemistry, Hematology, Coagulation, Urinalysis, Human Immunodeficiency Virus (HIV) test, Hepatitis A virus(HAV) test, Hepatitis B virus (HBV) test, Hepatitis C virus (HCV) test, syphilis, serum pregnancy tests and Breath Alcohol Test
measure: Peak Plasma Concentration (Cmax)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile and food effect of TG-1000.
measure: time to Cmax (Tmax)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile of TG-1000.
measure: area under the curve from time zero to the time (AUC0-t)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile and food effect of TG-1000.
measure: area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile of TG-1000.
measure: area under the concentration-time curve from time zero to infinity (AUC0-inf)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile and food Effect of TG-1000.
measure: terminal elimination half-life (T1/2, z)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile of TG-1000.
measure: apparent total body clearance (CL/F)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile of TG-1000.
measure: apparent total volume distribution (V/F)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile of TG-1000.
measure: plasma concentration 24 h after dosing (C24)
time frame: 15 days
description: Blood sample will be collected to evaluate PK profile of TG-1000.
measure: urinary excretion ratio relative to dose from time zero to the time (Feu0-t)
time frame: 15 days
description: Urine sample will be collected to evaluate PK profile of TG-1000.
arm group label: 10 mg TG-1000
arm group type: Experimental
description: Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.
arm group label: 20 mg TG-1000 or Placebo
arm group type: Experimental
description: Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.
arm group label: 40 mg TG-1000 or Placebo
arm group type: Experimental
description: Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
arm group label: 80 mg TG-1000 or Placebo
arm group type: Experimental
description: Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
arm group label: 120 mg TG-1000 or Placebo
arm group type: Experimental
description: Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
arm group label: 160 mg TG-1000 or Placebo
arm group type: Experimental
description: Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
arm group label: X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)
arm group type: Experimental
description: Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fasted condition. After washout period, subject will receive a single oral dose of TG-1000 under fed condition.
arm group label: X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)
arm group type: Experimental
description: Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fed condition. After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.
intervention type: Drug
intervention name: TG-1000
description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
arm group label: 10 mg TG-1000
arm group label: 120 mg TG-1000 or Placebo
arm group label: 160 mg TG-1000 or Placebo
arm group label: 20 mg TG-1000 or Placebo
arm group label: 40 mg TG-1000 or Placebo
arm group label: 80 mg TG-1000 or Placebo
arm group label: X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)
arm group label: X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)
intervention type: Drug
intervention name: Placebo
description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
arm group label: 120 mg TG-1000 or Placebo
arm group label: 160 mg TG-1000 or Placebo
arm group label: 20 mg TG-1000 or Placebo
arm group label: 40 mg TG-1000 or Placebo
arm group label: 80 mg TG-1000 or Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 45 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Pingsheng Xu
role: Principal Investigator
affiliation: Xiangya Hospital of Central South University
facility: 
country: China
responsible party type: Sponsor
sharing ipd: No